| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 | Dec'16 | Sep'16 | Jun'16 | Mar'16 | Dec'15 | Sep'15 | Jun'15 | Mar'15 | Dec'14 | Sep'14 | Jun'14 | Mar'14 | Sep'13 | Dec'12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating expenses: | ||||||||||||||||||||||||||
Research and development | ||||||||||||||||||||||||||
225,088 | 216,097 | 216,712 | 206,529 | 187,665 | 167,457 | 129,973 | 107,216 | 92,125 | 81,206 | 69,909 | 68,113 | 62,808 | 56,514 | 59,271 | 48,582 | 47,098 | 41,618 | 31,501 | 27,629 | 18,232 | 15,446 | 10,466 | 0 | 0 | 0 | 0 |
Research and development costs paid to Amgen | ||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | 0 | - |
In-process research and development license acquired from MSK | ||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 |
General and administrative | ||||||||||||||||||||||||||
77,399 | 79,584 | 81,086 | 78,933 | 74,885 | 69,654 | 61,124 | 55,321 | 45,698 | 40,326 | 34,575 | 30,653 | 27,534 | 24,728 | 24,987 | 21,993 | 19,100 | 16,830 | 16,839 | 14,401 | 12,158 | 12,710 | 8,030 | 0 | 0 | 0 | 0 |
Total operating expenses | ||||||||||||||||||||||||||
302,487 | 295,681 | 297,798 | 285,462 | 262,550 | 237,111 | 191,097 | 162,537 | 137,823 | 121,532 | 104,484 | 98,766 | 90,342 | 81,242 | 84,258 | 70,575 | 66,198 | 58,448 | 47,274 | 40,964 | 30,390 | 28,156 | 20,112 | 0 | 0 | 0 | 0 |
Loss from operations | ||||||||||||||||||||||||||
-302,487 | -295,681 | -297,798 | -285,462 | -262,550 | -237,111 | -191,097 | -162,537 | -137,823 | -121,532 | -104,484 | -98,766 | -90,342 | -81,242 | -84,258 | -70,575 | -66,198 | -58,448 | -47,274 | -40,964 | -30,390 | -28,156 | -20,112 | 0 | 0 | 0 | 0 |
Interest and other income, net | ||||||||||||||||||||||||||
4,271 | 4,717 | 5,259 | 6,457 | 6,993 | 6,368 | 5,084 | 3,789 | 2,527 | 2,027 | 2,073 | 2,085 | 2,209 | 2,203 | 2,206 | 2,010 | 1,568 | 1,218 | 762 | 412 | 272 | 125 | 62 | 0 | 0 | 0 | - |
Loss before provision for income taxes | ||||||||||||||||||||||||||
- | - | 0 | 0 | - | - | 0 | 0 | - | -119,505 | -102,411 | -96,681 | -88,133 | -79,039 | -82,052 | -68,565 | -64,630 | -57,230 | -46,512 | -40,552 | -30,118 | -28,031 | -20,050 | 0 | 0 | 0 | 0 |
Provision for (benefit from) income taxes | ||||||||||||||||||||||||||
- | - | 0 | 0 | - | - | 0 | 0 | - | -14 | 2 | 9 | 9 | 10 | 10 | -8 | -8 | -9 | -12 | -1 | -1 | -25 | -35 | 0 | 0 | 0 | 0 |
Net loss | ||||||||||||||||||||||||||
-298,228 | -290,976 | -292,492 | -278,958 | -255,513 | -230,699 | -186,000 | -158,735 | -135,280 | -119,491 | -102,413 | -96,690 | -88,142 | -79,049 | -82,062 | -68,557 | -64,622 | -57,221 | -46,500 | -40,551 | -30,117 | -28,006 | -20,015 | 0 | 0 | 0 | 0 |
Other comprehensive (loss) gain: | ||||||||||||||||||||||||||
Unrealized (loss) gain on available-for-sale securities | ||||||||||||||||||||||||||
166 | 560 | 682 | 678 | 562 | -189 | -361 | -391 | -372 | 32 | -123 | -307 | -203 | 335 | -16 | 259 | 69 | -418 | 62 | -66 | -7 | -100 | 0 | 0 | 0 | - | - |
Other comprehensive gain (loss) | ||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | - | - |
Comprehensive loss | ||||||||||||||||||||||||||
-298,062 | -290,416 | -291,810 | -278,280 | -254,951 | -230,888 | -186,361 | -159,126 | -135,652 | -119,459 | -102,536 | -96,997 | -88,345 | -78,714 | -82,078 | -68,298 | -64,553 | -57,639 | -46,438 | -40,617 | -30,124 | -28,106 | -20,026 | 0 | 0 | 0 | 0 |
Net loss per common share: | ||||||||||||||||||||||||||
Basic and diluted net loss per common share | ||||||||||||||||||||||||||
-1.20 | -1.32 | -1.31 | -1.60 | -1.44 | -1.78 | -1.29 | -1.15 | -1.05 | -1.16 | -1.02 | -0.94 | -0.88 | -0.63 | -0.88 | -0.66 | -0.58 | -0.77 | -0.43 | -0.62 | -0.42 | 7.53 | -4.20 | -3.37 | -5.58 | -2.59 | -5.60 |
Weighted-average shares outstanding used to calculate basic and diluted net loss per common share | ||||||||||||||||||||||||||
61,208 | 57,762 | 54,920 | 46,426 | 46,124 | 45,863 | 45,406 | 44,379 | 39,596 | 30,675 | 30,474 | 29,247 | 29,056 | 28,920 | 28,801 | 28,665 | 28,542 | 28,514 | 27,675 | 24,224 | 21,918 | -1,393,163 | 1,410,507 | 1,337 | 1,263 | 977 | 733 |